OncoSec Medical Incorporated (NASDAQ:ONCS) shares traded up 10.1% during trading on Wednesday . The company traded as high as $1.09 and last traded at $1.09. 647,330 shares traded hands during mid-day trading, an increase of 568% from the average session volume of 96,977 shares. The stock had previously closed at $0.99.

A number of research analysts have recently commented on the company. Dawson James restated a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a research note on Thursday, July 6th. ValuEngine upgraded OncoSec Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, July 14th. Maxim Group set a $5.00 target price on OncoSec Medical and gave the company a “buy” rating in a research note on Saturday, June 3rd. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of OncoSec Medical in a research note on Friday, June 2nd. Finally, Noble Financial restated a “buy” rating on shares of OncoSec Medical in a research note on Friday, May 12th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $5.33.

The company’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.13. The stock’s market capitalization is $22.86 million.

ILLEGAL ACTIVITY NOTICE: “OncoSec Medical Incorporated (ONCS) Trading 10.1% Higher” was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/09/08/oncosec-medical-incorporated-oncs-trading-10-1-higher.html.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.